Loading, Please Wait...
SANTA CLARA, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Landec Corporation (Nasdaq: LNDC), a diversified health and wellness company with two operating businesses, Curation Foods, Inc. and Lifecore Biomedical, Inc. reported results for the fiscal 2020 first quarter ended August 25, 2019. Landec plans to create shareholder value by delivering against our financial targets, investing in growth, strengthening our balance sheet, implementing our strategic priorities to improve operating margins at Curation Foods and driving topline momentum at Lifecore.
Dr. Albert Bolles, Landec’s President and CEO commented, “First quarter results met our guidance and we are set up for a successful year at both Lifecore and Curation Foods. We are investing capital at Lifecore to expand capacity and at Curation Foods to further automate our processing facilities and drive out costs. Our people are integral to our success and we are investing in talent across our entire organization to drive meaningful change. The results of these efforts are beginning to show in an improved culture at Landec, which is squarely focused on profitability and on executing with excellence with an emphasis on productivity to increase margins, while fostering a culture of sustainability.”
Fiscal First Quarter 2020 Financial Highlights
First fiscal quarter 2020 results compared to first fiscal quarter 2019 are as follows:
|(Unaudited and in thousands, except per-share data)||Three Months Ended||Change|
|August 25, 2019||August 26, 2018||Amount||%|
|Net (loss) income from continuing operations||(4,784||)||335||(5,119||)||N/||M|
|Diluted net (loss) income per share||$||(0.16||)||$||0.01||$||(0.17||)||N/||M|
*See “Non-GAAP Financial Information” at the end of this release for more information and for a reconciliation of certain financial information.
Revenues increased during the first quarter of fiscal 2020 primarily due to the addition of Yucatan Foods, which was acquired on December 1, 2018, that contributed $16.2 million in revenues and from a $2.2 million or 4% increase in salad revenues compared to the first quarter of last year. These increases were partially offset by: (1) a $3.2 million decrease in green bean revenues due to the extremely heavy rains and flooding in the Ohio Valley during May and June resulting in yields of 35% to 50% of normal, (2) a planned $1.4 million decrease in revenues in the packaged vegetables in bags and trays business, and (3) a $0.6 million planned decrease at Lifecore. The Lifecore decrease was a result of lower fermentation revenues during the first quarter of fiscal 2020 compared to the first quarter of fiscal 2019 due to the timing of shipments within fiscal 2020. The Lifecore revenue decrease was partially offset by a 49% increase in product development revenues due to an increase in development activities during the quarter.
Gross profit decreased during the first quarter of fiscal 2020 compared to the first quarter of last year primarily due to a $0.5 million decrease in the Curation Foods segment due to an unfavorable product mix and a $0.5 million decrease in the Lifecore segment as a result of a decrease in revenues and the timing of production within fiscal year 2020.
Net income decreased during the first quarter of fiscal 2020 compared to the first quarter of last year due to (1) a $1.0 million decrease in gross profit, (2) a $3.1 million increase in operating expenses primarily from the addition of Yucatan Foods, (3) a $1.3 million increase in interest expense due to the increase in debt from the acquisition of Yucatan Foods, and (4) no increase in the fair market value of the Company’s Windset investment compared to a $1.0 million increase during the first quarter of last year. These decreases in net income were partially offset by a $1.5 million decrease in income tax expenses.
EBITDA decreased during the first quarter of fiscal 2020 compared to the first quarter of last year due to the decrease in gross profit and from an increase in operating expenses primarily from the addition of Yucatan Foods partially offset by an increase in depreciation and amortization expenses.
|(Unaudited and in thousands)||Three Months Ended||Change|
|August 25, 2019||August 26, 2018||Amount||%|
|Total Gross Profit||$||15,336||$||16,337||$||(1,001||)||(6||)%|
|Net (Loss) Income from Continuing Operations:|
|Total Net (Loss) Income from Continuing Operations||$||(4,784||)||$||335||$||(5,119||)||N/||M|
|EBITDA, excluding Windset FMV change:|
|Total EBITDA excluding Windset FMV change||$||314||$||3,301||$||(2,987||)||(90||)%|
Update on Curation Foods Operational Initiatives Aligned with Company Priorities to Improve Profitability:
Update on Lifecore Momentum for Topline Growth:
Jim Hall, Lifecore’s President stated, “Our business continues to see momentum. Our expertise in pharmaceutical grade hyaluronan (HA) creates differentiation, high barriers to competition and unique business development opportunities. We are capitalizing on tailwinds in the CDMO marketplace and continue to be in an ideal position to meet increased demand from companies seeking a specialized CDMO partner. The planned decrease in revenues in the first quarter of fiscal 2020 was due to timing. We are on track to meet our 10 -12% overall yearly topline growth goal for fiscal 2020.”
Outlook and Fiscal 2020 Guidance (see Questions & Answers section at the end of this release for further details)
Greg Skinner Landec’s EVP of Finance and CFO commented, “We are reiterating our full year fiscal 2020 guidance and providing our forecast for fiscal second quarter. We plan to generate substantial profits in the second half of the fiscal year due to the timing of revenues and profits at Lifecore, the timing of revenues and profits from the sale of avocado products, and due to a large majority of the projected cost savings from our cost out initiatives occurring in the second half of fiscal 2020. Our capital allocation priorities remain focused on supporting the growth of both of our operating businesses while balancing that with efforts to reduce our leverage. We were in compliance with all our debt covenants at quarter end and expect to be in compliance going forward.”
The Company is reiterating its full year fiscal 2020 guidance as follows:
The Company is introducing fiscal second quarter 2020 guidance as follows:
“I have confidence in our guidance for fiscal 2020. At Lifecore, we will continue to expand and advance our development pipeline and invest in capacity to meet projected future demand. At Curation Foods, we will focus on four priorities for a strong financial performance. We will continue to simplify our business, focus on fewer new products that deliver high impact, and execute with operational excellence, while driving cost out. At Lifecore, we will continue to invest in topline growth by supporting business development opportunities and capacity expansion. I am confident that we have an action plan in place to make the changes necessary to be successful and secure long-term profitable growth. Lifecore and Curation Foods revenues, and more importantly profits, are expected to begin to ramp up during the third and fourth quarters, at the same time as the changes we have outlined begin to take hold,” concluded Bolles.
The live webcast can be accessed directly at http://ir.Landec.com/events.cfm or on Landec’s website on the Investor Events & Presentations page. The webcast will be available for 30 days.
Date: Wednesday, October 2, 2019
Time: 11:00 a.m. Eastern time (8:00 a.m. Pacific time)
Direct Webcast link: http://ir.Landec.com/events.cfm
To participate in the conference call via telephone, dial toll-free (877) 407-3982 or (201) 493-6780. Please call the conference telephone number 5-10 minutes prior to the start time so the operator can register your name and organization. If you have any difficulty with the webcast or connecting to the call, please contact ICR at (646) 277-1254.
A replay of the call will be available through Wednesday, October 9, 2019 by calling toll-free (844) 512-2921 or direct (412) 317-6671, and entering code 13694436.
About Landec Corporation
Landec Corporation (Nasdaq: LNDC) is a leading innovator of diversified health and wellness solutions with two operating businesses: Curation Foods, Inc. and Lifecore Biomedical, Inc. Curation Foods is focused on innovating and distributing plant-based foods with 100% clean ingredients to retail, club and foodservice channels throughout North America. Curation Foods is able to maximize product freshness through its geographically dispersed family of growers, refrigerated supply chain and patented BreatheWay® packaging technology. Curation Foods brands include Eat Smart® fresh packaged vegetables and salads, O Olive Oil & Vinegar® premium artisan products, and Yucatan® and Cabo Fresh® avocado products. Lifecore Biomedical is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of difficult to manufacture pharmaceutical products in syringes and vials. As a leading manufacturer of premium, injectable grade Hyaluronic Acid, Lifecore brings 35 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Landec’s website at www.landec.com.
Non-GAAP Financial Information
This press release contains non-GAAP financial information relating to EBITDA. The Company has included a reconciliation of this non-GAAP financial measure to the most directly comparable financial measure calculated in accordance with GAAP. See the end of this release for these reconciliations.
The Company has disclosed this non-GAAP financial measure to supplement its consolidated financial statements presented in accordance with GAAP. This non-GAAP financial measure excludes/includes certain items that are included in the Company’s results reported in accordance with GAAP. Management believes these non-GAAP financial measures provide useful additional information to investors about trends in the Company’s operations and are useful for period-over-period comparisons. This non-GAAP financial measure should not be considered in isolation or as a substitute for the comparable GAAP measures. In addition, this non-GAAP financial measure may not be the same as similar measures provided by other companies due to the potential differences in methods of calculation and items being excluded/included. It should be read in conjunction with the Company’s consolidated financial statements presented in accordance with GAAP.
Important Cautions Regarding Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially, including such factors among others, as the timing and expenses associated with operations, the ability to achieve acceptance of the Company's new products in the market place, weather conditions that can affect the supply and price of produce, government regulations affecting our business; the timing of regulatory approvals, the ability to successfully integrate Yucatan Foods into the Curation Foods business, and the mix between domestic and international sales. For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to our filings with the Securities and Exchange Commission (“SEC”), including the risk factors contained in our most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K. Forward-looking statements represent management’s current expectations and are inherently uncertain. Except as required by law, we do not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.
CONSOLIDATED CONDENSED BALANCE SHEETS
|August 25, 2019||May 26, 2019|
|Cash and cash equivalents||$||1,990||$||1,080|
|Accounts receivable, net||61,402||69,565|
|Prepaid expenses and other current assets||12,150||8,264|
|Total Current Assets||130,562||133,041|
|Investment in non-public company||61,100||61,100|
|Property and equipment, net||201,557||200,027|
|Customer relationships, net||14,807||15,319|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Other accrued liabilities||8,790||10,001|
|Current portion of lease liabilities||3,601||75|
|Line of credit||70,600||52,000|
|Current portion of long-term debt||9,791||9,791|
|Other current liabilities, discontinued operations||—||65|
|Total Current Liabilities||146,831||137,091|
|Long-term debt, less current portion||84,748||87,193|
|Long-term lease liabilities||30,026||3,532|
|Other non-current liabilities||1,899||1,738|
|Additional paid-in capital||160,814||160,341|
|Accumulated other comprehensive income||(548||)||64|
|Total Stockholders’ Equity||264,947||270,144|
|Total Liabilities and Stockholders’ Equity||$||546,137||$||519,091|
CONSOLIDATED CONDENSED STATEMENTS OF INCOME
(In thousands, except per-share data)
|Three Months Ended|
|August 25, 2019||August 26, 2018|
|Cost of product sales||123,378||108,331|
|Operating costs and expenses:|
|Research and development||2,821||2,791|
|Selling, general and administrative||16,895||13,803|
|Total operating costs and expenses||19,716||16,594|
|Net (loss) income from continuing operations before taxes||(6,149||)||444|
|Income tax benefit (expense)||1,365||(109||)|
|Net (loss) income from continuing operations||(4,784||)||335|
|Loss from discontinued operations||—||(190||)|
|Income tax benefit||—||45|
|Loss from discontinued operations||—||(145||)|
|Net (loss) income available to common stockholders||$||(4,784||)||$||190|
|Diluted net (loss) income per share from continuing operations||$||(0.16||)||$||0.01|
|Diluted net (loss) per share from discontinued operations||$||—||$||—|
|Diluted net (loss) income per share||$||(0.16||)||$||0.01|
|Shares used in diluted per share computations||29,139||28,020|
FIRST QUARTER ENDED AUGUST 25, 2019
QUESTIONS & ANSWERS
1) What gives you confidence you can go from a loss for the first six months of fiscal 2020 to your EPS guidance of $0.28 to $0.32 for the fiscal year?
There are five primary factors that gives us confidence in being able to achieve our fiscal 2020 EPS guidance:
a. Lifecore plans to recognize approximately 65% of its revenues and 80% of its operating income during the second half of fiscal 2020, in line with historical results based on customer order patterns. And Lifecore has a very good track record of meeting or exceeding its plan on a fiscal year basis.
b. Avocado products production began over three months earlier than last year with a fully trained labor force which will result in a much higher level of efficiency and productivity. Starting production this early will also allow us to complete production in the late April to early May timeframe before the cost of avocados typically increase.
c. A large majority of the projected $18 million to $20 million in cost savings from our cost out initiatives will be recognized during the second half of fiscal 2020 as a result of the new automation being installed primarily during the first half of fiscal 2020. Because the cost increases went into effect at the beginning of fiscal 2020 and the majority of the cost savings won’t be realized until the second half of fiscal 2020, the projected cost increases will have a net negative impact during the first half of the year and a net positive impact during the second half of the year.
d. New initiatives we have implemented in the area of food safety, new packaging, network optimization and information technology are going to start benefiting the Company in the second half of fiscal 2020 and beyond.
e. We expect the growth of salads to accelerate during the second half of fiscal 2020 and we expect green beans to rebound from the sourcing issues experienced during the first quarter of fiscal 2020 and be profitable for the remainder of the year.
2) What are the expectations for Lifecore’s business development pipeline?
Lifecore currently has approximately fifteen FDA regulated drug and medical device products in its development pipeline that are in various stages of development and that range from early phase pre-clinical work to late phase pivotal clinical studies. It is important to understand that Lifecore does not own the regulatory submission process or the Design History File of the products that we are developing with our partners. Lifecore actively supports the submission process by providing the necessary documentation requested by our partners and by hosting the regulatory agencies who audit Lifecore as part of the regulatory approval process (Pre-Approval Inspections). Lifecore anticipates that at least 1-2 of the current products under development will be commercially approved within the next 24 months. Moving forward Lifecore is working towards having a pipeline that provides an average of 1 to 2 products that receive commercial approval annually.
3) What are the projected cost savings in fiscal 2020 from the Curation Foods cost out initiatives?
Curation Foods is projecting cost savings of $18 million to $20 million in fiscal 2020. A majority of the capital expenditures in the Curation Foods business during fiscal 2020 is for new automation associated with the cost out program. The acquisition and installation of the new automation is in progress and therefore a large majority of the savings will be realized during the second half of the fiscal year.
The cost savings realized during fiscal 2020 from the cost out initiatives will be used to offset projected price increases, primarily due to increased labor, freight and raw material sourcing costs. In addition, we have set aside in our plan and guidance a contingency for unforeseeable produce sourcing issues which we believe is more than adequate to cover sourcing issues during the last three quarters of fiscal 2020.
4) What is the Company’s current leverage ratio and borrowing capacity?
At the end of the first quarter of fiscal 2020 the Company’s debt-to-equity ratio was 62% and our debt-to-tangible assets ratio was 39%. Our fixed coverage ratio at the end of fiscal 2019 was 1.9 which is well above our covenant of 1.2 or greater. Our leverage ratio at the end of fiscal 2019 was 4.4, and our debt covenant is 4.5 or less. At the end of the first quarter our borrowing availability was less than $10 million, however, based on projected positive cash flow from operations over the remainder of fiscal 2020, coupled with the expected amended debt agreement described in (5) below, we expect to have adequate liquidity to continue to grow our business and invest in capital to advance both our Curation and Lifecore businesses.
5) What is the Company’s plan for reducing its leverage ratio and/or debt during fiscal 2020?
The Company is in late stage discussions with its banks (JPMorgan, BMO and City National Bank) to amend its current debt agreement. We are discussing a financing structure that will extend the term of our debt, increase the amount of availability and amend our current covenants. The amendment should give us the necessary liquidity, along with cash flows from operations, to accelerate our cost out automation projects at Curation Foods and to expand our capacity at Lifecore. We expect the amendment to be completed within the next 30 days.
6) What are Landec’s top priorities for the next 12 to 24 months?
Our top priorities over the next 12-24 months are:
Non-GAAP Financial Information and Reconciliations
The table below presents the reconciliation of a non-GAAP financial measure to the most directly comparable financial measure calculated in accordance with GAAP and other supplemental information. See “Non-GAAP Financial Information” above for further information regarding the Company’s use of non-GAAP financial measures.
|(Unaudited and in thousands)||Three Months Ended|
|August 25, 2019||August 26, 2018|
|Net (loss) income from continuing operations||$||(4,784||)||$||335|
|FMV change in Windset investment||—||(1,000||)|
|Net interest expense||2,050||712|
|Total EBITDA excluding Windset FMV change||$||314||$||3,301|
|At the Company:||Investor Relations:|
|Gregory S. Skinner||Jeff Sonnek|
|Executive Vice President Finance and Administration and CFO||(646) 277-1263|